GLP-1 Medications Without a Primary Care Doctor: What Telehealth Actually Requires

One of the most frequent questions patients ask when researching GLP-1 access is some version of the same thing: Do I need my family doctor to refer me, or can I go directly? The answer, for telehealth-based GLP-1 programs, is that no referral from a primary care physician is required. What is required—and what cannot be bypassed without entering medically and legally compromised territory—is a genuine clinical evaluation by a licensed prescribing physician.

These two things are often conflated, and the conflation matters. The absence of a PCP in the process does not mean the absence of physician judgment. Understanding what legitimate telehealth programs do, and what problematic ones skip, is useful for patients trying to assess their options honestly.

The Regulatory Foundation: Who Can Prescribe

GLP-1 receptor agonists are Schedule unscheduled but prescription-only medications in the United States. Any licensed physician, nurse practitioner, or physician assistant with prescriptive authority can issue a prescription for a GLP-1 medication, provided they have established a valid patient-physician relationship and conducted a clinical evaluation sufficient to support the prescribing decision.

A telehealth physician can satisfy this requirement. The evaluation does not need to occur in person—post-pandemic telehealth regulations have permanently expanded the conditions under which a valid prescribing relationship can be established via video or asynchronous clinical intake. There is no legal requirement that a primary care physician be involved at any point. A patient who has never had a PCP, or who has not seen their PCP in years, is not disqualified from accessing GLP-1 medications through a legitimate telehealth platform.

What is not permissible—and what some lower-quality platforms have been found to do—is issuing a prescription based on a self-reported health questionnaire alone, without physician review of the clinical data or any real clinical decision-making. That is not a valid patient-physician relationship, and the prescriptions generated through such processes are legally and ethically suspect.

What a Legitimate Telehealth Evaluation Actually Includes

The clinical minimum for a GLP-1 prescribing evaluation is not codified in a single federal standard—it is defined by the standard of care for obesity medicine and by state medical board requirements for telehealth prescribing. Across reputable programs, the evaluation consistently includes several components.

Structured health intake

Before any physician interaction, legitimate platforms collect a comprehensive medical history: current and past diagnoses, current medications, allergies, family history of relevant conditions (particularly thyroid cancer and MEN2 syndrome, which are absolute contraindications), and a weight history. This is not the same as a simple eligibility questionnaire—it is clinical information that a physician uses to assess appropriateness and risk.

Biometric verification

Most platforms require self-reported height and weight to calculate BMI, which is the primary eligibility criterion. Better programs explicitly request a recent blood pressure reading and may ask for recent laboratory values. Some require patients to upload documentation from a recent clinical encounter to verify vital signs. Platforms that ask for nothing verifiable beyond a name and credit card have no meaningful ability to assess clinical eligibility.

Physician review and decision

A licensed physician must personally review the intake data and make a clinical determination. This review may occur synchronously (video visit) or asynchronously (chart review with a written note), depending on the platform model and the patient’s state of residence. The outcome of this review is either a prescription with documented clinical rationale, a request for additional information, or a decline with explanation.

The clinical rationale documented in the physician’s note should address, at minimum: the patient’s BMI and relevant comorbidities, the absence of contraindications, the selected medication and dose escalation plan, and any monitoring requirements. A platform that cannot provide patients with access to this documentation on request is not operating transparently.

Ongoing monitoring structure

The initial evaluation is only part of the clinical relationship. GLP-1 dose escalation occurs over 16–20 weeks, and during that period patients require monitoring for side effect tolerance, response to treatment, and periodic reassessment of clinical parameters. Legitimate programs schedule follow-up visits—typically at 4–8 week intervals during escalation, then every 60–90 days during maintenance—and have structured protocols for managing common adverse events like nausea or dose-limiting gastrointestinal symptoms.

Programs that issue a prescription and then provide no structured follow-up create a situation in which patients are self-managing a complex dose escalation without clinical support. This is not an acceptable standard of care, and patients who experience adverse events in this context have no clear pathway for help.

What Varies by State

While no state requires a PCP referral for GLP-1 prescribing, state medical boards set the rules governing telehealth prescribing within their jurisdictions. Several dimensions of the prescribing process vary meaningfully by state:

Warning Signs in Telehealth GLP-1 Programs

Not all platforms operate at the same clinical standard. The following characteristics are worth scrutinizing before committing to any program:

• No physician name disclosed: Patients have a right to know who is prescribing their medication. Platforms that obscure or do not disclose the prescribing physician’s identity are operating outside normal standards of transparency.
• Prescription issued within minutes of intake: A thorough clinical review cannot be completed in minutes. Immediate prescription delivery after a short questionnaire suggests the “evaluation” is not receiving genuine physician attention.
• No follow-up structure: Programs that describe their model as “one prescription, then self-managed” are not providing physician-supervised care.
• No contraindication screening: Any program that does not ask about thyroid cancer history, MEN2 history, or pancreatitis before prescribing a GLP-1 is not conducting a safe clinical evaluation.
• No mechanism for side effect management: Dose escalation produces side effects in a significant proportion of patients. Programs with no clear pathway for clinical support during this period are not adequately equipped to manage what will happen.

When a Primary Care Doctor Is Still Worth Involving

While no PCP referral is required, there are clinical situations in which involving an existing primary care physician adds genuine value to the process—not as a gatekeeper, but as a clinical resource.

Patients with complex medical histories—multiple cardiovascular medications, kidney disease, a history of pancreatitis, or significant gastrointestinal conditions—benefit from having their GLP-1 prescribing coordinated with a physician who knows their full clinical picture. Telehealth platforms conducting an intake evaluation see a snapshot; a PCP with years of history sees the full context.

Patients who are on medications that interact with GLP-1–mediated glucose lowering (particularly sulfonylureas or insulin in patients with type 2 diabetes) should also have their existing prescribing physician aware that a GLP-1 is being added, because dose adjustments to existing medications may be required to prevent hypoglycemia.

None of this requires the PCP to initiate or approve the process. It simply reflects the clinical reality that GLP-1 medications exist within a broader health context, and good care accounts for that context.